Zymeworks Inc.
ZYME Real Time Price USDRecent trades of ZYME by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by ZYME's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
ZYME Revenue by Segment or Geography
New patents grants
-
Patent Title: Antigen-binding constructs targeting her2 Feb. 18, 2025
-
Patent Title: Bispecific antigen binding constructs targeting her2 Feb. 04, 2025
-
Patent Title: Methods of using bispecific antigen-binding constructs targeting her2 Dec. 03, 2024
-
Patent Title: Methods of using a bispecific antigen-binding construct targeting her2 in combination with cdk4/6 inhibitors for the treatment of breast cancer Sep. 03, 2024
-
Patent Title: Engineered immunoglobulin heavy chain-light chain pairs and uses thereof Aug. 13, 2024
-
Patent Title: Bispecific antigen-binding constructs targeting her2 Apr. 23, 2024
-
Patent Title: Stabilized chimeric fabs Apr. 23, 2024
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to ZYME
Number of mentions of ZYME in WallStreetBets Daily Discussion
Recent picks made for ZYME stock on CNBC
ETFs with the largest estimated holdings in ZYME
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $ZYME stock a Buy, Sell, or Hold?
- What is the price target for $ZYME stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $ZYME stock?
- Who owns the most shares of $ZYME stock?
- What funds own $ZYME stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ZYME Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.